Forte Biosciences shareholders elect two Class II directors, ratify auditor, approve equity plan

Forte Biosciences, Inc.

Steven Kornfeld elected Class II director with 3,366,874 votes for; Patricia Walker with 3,335,739 for, 1,612,841 withheld; 3,373,670 broker non-votes.
Ratification of Mayer Hoffman McCann as independent auditor for FY2022: 8,107,698 for, 157,062 against, 57,490 abstentions.
Increase to 2021 Equity Incentive Plan approved: 2,826,803 for, 2,106,190 against, 15,587 abstentions, 3,373,670 broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.